Cempra Pharmaceuticals to Present at the Lazard 7th Annual Healthcare Conference

CHAPEL HILL, N.C., Nov. 15, 2010 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Lazard 7th Annual Healthcare Conference at 9:00 a.m. EST, November 17, 2010, at the St. Regis New York in New York City.  Dr. Fernandes will provide an update on the company's two leading antibiotic clinical programs, solithromycin (CEM-101), a fluoroketolide for community-acquired bacterial pneumonia and other infections and TAKSTA™ (sodium fusidate, formerly CEM-102) for the oral treatment of gram positive pathogens including MRSA.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

SOURCE Cempra Pharmaceuticals